FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885246511> ?p ?o ?g. }

• W2885246511 endingPage "281" @default.
• W2885246511 startingPage "270" @default.
• W2885246511 abstract "Background Covert vascular disease of the brain manifests as infarcts, white matter hyperintensities, and microbleeds on MRI. Their cumulative effect is often a decline in cognition, motor impairment, and psychiatric disorders. Preventive therapies for covert brain ischemia have not been established but represent a huge unmet clinical need. Aims The MRI substudy examines the effects of the antithrombotic regimens in COMPASS on incident covert brain infarcts (the primary outcome), white matter hyperintensities, and cognitive and functional status in a sample of consenting COMPASS participants without contraindications to MRI. Methods COMPASS is a randomized superiority trial testing rivaroxaban 2.5 mg bid plus acetylsalicylic acid 100 mg and rivaroxaban 5 mg bid against acetylsalicylic acid 100 mg per day for the combined endpoint of MI, stroke, and cardiovascular death in individuals with stable coronary artery disease or peripheral artery disease. T1-weighted, T2-weighted, T2*-weighted, and FLAIR images were obtained close to randomization and near the termination of assigned antithrombotic therapy; biomarker and genetic samples at randomization and one month, and cognitive and functional assessment at randomization, after two years and at the end of study. Results Between March 2013 and May 2016, 1905 participants were recruited from 86 centers in 16 countries. Of these participants, 1760 underwent baseline MRI scans that were deemed technically adequate for interpretation. The mean age at entry of participants with interpretable MRI was 71 years and 23.5% were women. Coronary artery disease was present in 90.4% and 28.1% had peripheral artery disease. Brain infarcts were present in 34.8%, 29.3% had cerebral microbleeds, and 93.0% had white matter hyperintensities. The median Montreal Cognitive Assessment score was 26 (interquartile range 23–28). Conclusions The COMPASS MRI substudy will examine the effect of the antithrombotic interventions on MRI-determined covert brain infarcts and cognition. Demonstration of a therapeutic effect of the antithrombotic regimens on brain infarcts would have implications for prevention of cognitive decline and provide insight into the pathogenesis of vascular cognitive decline." @default.
• W2885246511 created "2018-08-22" @default.
• W2885246511 creator A5001064258 @default.
• W2885246511 creator A5010571732 @default.
• W2885246511 creator A5011747612 @default.
• W2885246511 creator A5013048501 @default.
• W2885246511 creator A5013408607 @default.
• W2885246511 creator A5015783013 @default.
• W2885246511 creator A5016752955 @default.
• W2885246511 creator A5018419311 @default.
• W2885246511 creator A5021591848 @default.
• W2885246511 creator A5024040536 @default.
• W2885246511 creator A5026568725 @default.
• W2885246511 creator A5033034869 @default.
• W2885246511 creator A5035977661 @default.
• W2885246511 creator A5039145780 @default.
• W2885246511 creator A5039381247 @default.
• W2885246511 creator A5039466154 @default.
• W2885246511 creator A5041291525 @default.
• W2885246511 creator A5042971997 @default.
• W2885246511 creator A5046836572 @default.
• W2885246511 creator A5047724596 @default.
• W2885246511 creator A5055052720 @default.
• W2885246511 creator A5055606506 @default.
• W2885246511 creator A5066263534 @default.
• W2885246511 creator A5068256830 @default.
• W2885246511 creator A5072015543 @default.
• W2885246511 creator A5074560590 @default.
• W2885246511 creator A5078471246 @default.
• W2885246511 creator A5079046512 @default.
• W2885246511 creator A5080292021 @default.
• W2885246511 creator A5082101100 @default.
• W2885246511 creator A5083111944 @default.
• W2885246511 creator A5084986659 @default.
• W2885246511 creator A5086287744 @default.
• W2885246511 creator A5086609118 @default.
• W2885246511 creator A5087101589 @default.
• W2885246511 creator A5087630518 @default.
• W2885246511 creator A5088186128 @default.
• W2885246511 creator A5088775153 @default.
• W2885246511 date "2018-07-30" @default.
• W2885246511 modified "2023-10-12" @default.
• W2885246511 title "Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial" @default.
• W2885246511 cites W2009483243 @default.
• W2885246511 cites W2016349161 @default.
• W2885246511 cites W2023663258 @default.
• W2885246511 cites W2049729574 @default.
• W2885246511 cites W2074937504 @default.
• W2885246511 cites W2091931051 @default.
• W2885246511 cites W2096447804 @default.
• W2885246511 cites W2102509688 @default.
• W2885246511 cites W2104855192 @default.
• W2885246511 cites W2108329377 @default.
• W2885246511 cites W2117167194 @default.
• W2885246511 cites W2124681501 @default.
• W2885246511 cites W2134172803 @default.
• W2885246511 cites W2146657064 @default.
• W2885246511 cites W2148568506 @default.
• W2885246511 cites W2158742097 @default.
• W2885246511 cites W2159039256 @default.
• W2885246511 cites W2165758561 @default.
• W2885246511 cites W2527609605 @default.
• W2885246511 cites W2566738615 @default.
• W2885246511 cites W2621785677 @default.
• W2885246511 cites W2749380187 @default.
• W2885246511 cites W4296588155 @default.
• W2885246511 doi "https://doi.org/10.1177/1747493018784478" @default.
• W2885246511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30058959" @default.
• W2885246511 hasPublicationYear "2018" @default.
• W2885246511 type Work @default.
• W2885246511 sameAs 2885246511 @default.
• W2885246511 citedByCount "12" @default.
• W2885246511 countsByYear W28852465112019 @default.
• W2885246511 countsByYear W28852465112020 @default.
• W2885246511 countsByYear W28852465112021 @default.
• W2885246511 countsByYear W28852465112023 @default.
• W2885246511 crossrefType "journal-article" @default.
• W2885246511 hasAuthorship W2885246511A5001064258 @default.
• W2885246511 hasAuthorship W2885246511A5010571732 @default.
• W2885246511 hasAuthorship W2885246511A5011747612 @default.
• W2885246511 hasAuthorship W2885246511A5013048501 @default.
• W2885246511 hasAuthorship W2885246511A5013408607 @default.
• W2885246511 hasAuthorship W2885246511A5015783013 @default.
• W2885246511 hasAuthorship W2885246511A5016752955 @default.
• W2885246511 hasAuthorship W2885246511A5018419311 @default.
• W2885246511 hasAuthorship W2885246511A5021591848 @default.
• W2885246511 hasAuthorship W2885246511A5024040536 @default.
• W2885246511 hasAuthorship W2885246511A5026568725 @default.
• W2885246511 hasAuthorship W2885246511A5033034869 @default.
• W2885246511 hasAuthorship W2885246511A5035977661 @default.
• W2885246511 hasAuthorship W2885246511A5039145780 @default.
• W2885246511 hasAuthorship W2885246511A5039381247 @default.
• W2885246511 hasAuthorship W2885246511A5039466154 @default.
• W2885246511 hasAuthorship W2885246511A5041291525 @default.
• W2885246511 hasAuthorship W2885246511A5042971997 @default.
• W2885246511 hasAuthorship W2885246511A5046836572 @default.
• W2885246511 hasAuthorship W2885246511A5047724596 @default.
• W2885246511 hasAuthorship W2885246511A5055052720 @default.

• next